BioSpace News Archive

Updates 2019 GAAP Diluted EPS Guidance Range to $7.26 to $7.36; Raises 2019 Adjusted Diluted EPS Guidance Range From $8.65 to $8.75 to $8.73 to $8.83, Representing Growth of 11.0 Percent at the Midpoint

New drug disposal technology supplements drug drops-offs at take-back days and kiosks with an at-home, site-of-use solution that prevents the misuse of unused medications

CEO and founder, Rob Zondervan, PhD, and Lansing-based company unveils CleanCase sterile mobile device technology to improve patient care, limit infections

BioLabs@NYULangone today announced that MEND, a company developing nutritional interventions to enhance patient outcomes across a range of conditions, has been selected as the newest resident of the biotech coworking facility.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), for patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis

Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO), a leading science-focused, multi-state cannabis company, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for its patent application titled, “Tobacco Products with Cannabinoid Additives and Methods for Reducing the Harm Associated with Tobacco Use.”

Medneon, a digital health company, today announced the launch of a groundbreaking clinicogenetic patient registry to investigate whether identifying high-risk individuals and managing their genetic mutations over time can prevent hereditary breast cancer.

Hologic, Inc. (Nasdaq: HOLX) today announced global commercial availability of the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2019.

International biotech company Dante Labs announced today the offer of whole genome sequencing (WGS) with interpretation for only $229 (€199).